Bull
$539.08
情景价格
$622.180
-8.399 (-1.35%)收盘时
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
Thermo Fisher Scientific Inc is a good buy right now, trading at $622.18 with a forward P/E of 25.25, indicating potential for growth relative to its earnings. The stock has shown a strong year-over-year performance with a 27.62% increase and is favored by hedge funds, as highlighted by Goldman Sachs' report. However, a key risk is the current RSI of 57.01, suggesting it is nearing overbought territory.
Piper Sandler
$600
2026-07-27
Piper Sandler
2026-07-27
目标价
$600
Morgan Stanley
$650
2026-07-24
Morgan Stanley
2026-07-24
目标价
$650
RBC Capital
$580
2026-07-24
RBC Capital
2026-07-24
目标价
$580
Barclays
$650
2026-07-24
Barclays
2026-07-24
目标价
$650
BofA
$650
2026-07-23
BofA
2026-07-23
目标价
$650
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Goldman Sachs: Hedge Fund and Mutual Fund Favorite Stocks

Divergent Recovery Paths in Healthcare Sector

Comparing Growth Strategies: Abbott vs. Thermo Fisher

S&P 500 Ends Three-Week Winning Streak Amid Rising Treasury Yields

Three Profitable Stocks to Be Wary Of
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).
Thermo Fisher Scientific Inc is a good buy right now, trading at $622.18 with a forward P/E of 25.25, indicating potential for growth relative to its earnings. The stock has shown a strong year-over-year performance with a 27.62% increase and is favored by hedge funds, as highlighted by Goldman Sachs' report. However, a key risk is the current RSI of 57.01, suggesting it is nearing overbought territory.
15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。